New donor cell therapy shows promise for tough blood cancers
NCT ID NCT04620681
First seen Nov 01, 2025 · Last updated May 31, 2026 · Updated 32 times
Summary
This study tested an experimental treatment for people with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (AML) whose first therapy stopped working. Nineteen adults received a special infusion of immune cells from a mismatched unrelated donor, designed to attack the cancer without permanently taking over the bone marrow. The main goal was to find a safe dose and see if the treatment could control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.